
Why Drugmakers Are Delaying European Launches as U.S. Pricing Pressure Reshapes Global Access
Some pharmaceutical companies are slowing European drug launches while monitoring U.S. pricing pressure and policy uncertainty. The delays could reshape which patients get treatment first and whether pricing politics in one major market affect health access worldwide.










